Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

Study Identifier:
D9281R00002
ClinicalTrials.gov Identifier:
NCT06967480
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
1-855-752-2356 or [email protected]
Will Be Recruiting

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Ravulizumab
Date
Jun 2025 - May 2027
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Ravulizumab
Date
Jun 2025 - May 2027
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information

Protocol Summary

The primary objective of the study is to evaluate the effectiveness of Ravulizumab in improving MG-ADL in an early-stage AChR+ gMG population.

Trial Locations

Location
Status
Location
Clinical Trial Site
Bergamo, Italy
Status
N/A
Location
Clinical Trial Site
Bologna, Italy
Status
N/A
Location
Clinical Trial Site
Brescia, Italy
Status
N/A
Location
Clinical Trial Site
Firenze, Italy
Status
N/A
Location
Clinical Trial Site
Imperia, Italy
Status
N/A
Location
Clinical Trial Site
Lecco, Italy
Status
N/A